Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8838290 | 1.00 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL155187 | 1.00 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7858967 | 1.00 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9949427 | 1.00 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL8501137 | 1.00 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL23149781 | 1.00 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL2532247 | 0.97 | MEN1 (0.52) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL7702021 | 0.95 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL4293421 | 0.95 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL14360432 | 0.95 | MEN1 (0.56) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-4795814-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTTS, ENZYME INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| US-4739053-A | CHARGE CARRIER-TRANSPORTING COMPOUNDS; ELECTROGRAPHY | BASF AKTIENGESELLSCHAFT (DE) | 1988-04-19 | — | — | US | disclosed |
| EP-0116341-B1 | 2H-V-TRIAZOLYL(4,5-D)-PYRIMIDINES AND THEIR USE | BASF Aktiengesellschaft (DE) | 1986-05-07 | — | — | EP | disclosed |
| EP-0173126-A1 | Process for preparing novel dihydropyridine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0162216-A1 | 2,4,5-Triphenyl-1,2,3-triazoles and thier use | BASF Aktiengesellschaft (DE) | 1985-11-27 | — | — | EP | disclosed |
| EP-0156308-A2 | Pyrazolo-[3,4-d]v-triazoles and their use | BASF Aktiengesellschaft (DE) | 1985-10-02 | — | — | EP | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0116341-A1 | 2H-V-Triazolyl(4,5-D)-pyrimidines and their use | BASF Aktiengesellschaft (DE) | 1984-08-22 | — | — | EP | disclosed |
| US-4136100-A | BLUE-VIOLET TO GREEN-BLUE DYEINGS ON CELLULOSE TEXTILES | BASF AKTIENGESELLSCHAFT (DE) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | IMPA1, IMPDH1, TYMP | MEN1 4734/4885THRB 4167/4885HTT 3834/4885 |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | IMPDH1, IMPDH2, SAV1 | MEN1 4302/4885THRB 2687/4885HTT 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.